The first PI3K/AKT/mTOR pathway inhibitors developed targeting mTORC1, everolimus and temsirolimus, are the most widely investigated mTOR inhibitors for ovarian cancer. This evidence concerns the gene PIK3CB and ovarian carcinoma.